Refine by
Drug Conjugates Articles & Analysis
66 news found
Watertown, MA - June 29, 2025 - Biopharma PEG, a leading innovator in high-quality polyethylene glycol (PEG) derivatives, today announced it has successfully obtained Drug Master File (DMF) approval from the U.S. Food and Drug Administration (FDA) for its self-developed HZ-PEG-HZ (1K) product. ...
Biopharma PEG, a leading manufacturer of high-quality polyethylene glycol (PEG) derivatives, today announced that its mPEG-pAld (20K) product has successfully achieved DMF (Drug Master File) registration with the U.S. Food and Drug Administration (FDA) under DMF number 040600. ...
They are also critical components in antibody-drug conjugate (ADC) linkers, facilitating targeted drug delivery, and in PROTAC linkers, enabling the development of novel protein degradation therapies. ...
This iterative process facilitates the creation of drug candidates that not only show promise in early trials but are also more likely to advance through the rigorous drug development pipeline. ...
In the rapidly evolving landscape of pharmaceutical innovations, CD Formulation emerges as a key player, offering customized drug conjugates services that cater to the rising demands for advanced drug development. ...
Kelly Bugatti, BOC Sciences is set to host an informative webinar that will delve into the latest advancements in utilizing Peptide-Drug Conjugates (PDCs) for the targeted treatment of Pulmonary Fibrosi BOC Sciences has been organizing regular webinars in the fields of life sciences, drug discovery, and chemistry. ...
Changsha, China – Hunan Huateng Pharmaceutical Co., Ltd. is proud to provide high-quality monodispersed polyethylene glycols (PEGs) tailored for the evolving needs of antibody-drug conjugates (ADCs). With the ADC market surpassing $10 billion in 2023 and projected to reach $13.13 billion by 2030, our commitment to innovation and quality is stronger than ...
Tempus, a leader in artificial intelligence and precision medicine, announced new testing solutions to help physicians identify patients with HER2 or FOLR1 expressing tumors, which may make such patients eligible for targeted therapies such as antibody–drug conjugates (ADCs). HER2 and FOLR1 testing by immunohistochemistry (IHC) is now available for ...
ByTempus
This efficient and highly modular approach has applications in a wide range of fields, including drug discovery, materials science, and bioconjugation. Alfa Chemistry's expanded range of click chemistry reagents now includes DBCO, BCN, and Tetrazines. ...
Biopharma PEG, a leading name in the pharmaceutical industry, is proud to announce a groundbreaking advancement in the field of Antibody-Drug Conjugate (ADC) development. The company now offers monodispersed Polyethylene Glycols (PEGs) on a scale ranging from grams to kilograms, and even on a ton scale. ...
Biopharma PEG, a leading provider of innovative solutions for the pharmaceutical industry, is proud to announce an extensive inventory of monodispersed PEGs (Polyethylene Glycols) that cater to a wide range of applications, including Antibody Drug Conjugates (ADCs), PROTACs, drug delivery systems, and more. Our comprehensive collection includes ...
By leveraging cutting-edge conjugation methods, targeting drug delivery solutions, and RNAi delivery systems, scientists can gain unprecedented control over the design and synthesis of bioconjugates. ...
BOC Sciences, a leading CRO in the USA, unveils its comprehensive capabilities for custom peptide drug conjugate from project design to commercial production. With its well-established conjugation platform, BOC Sciences supports pharmaceutical and biotechnology clients at the forefront of drug conjugation. ...
Araris Biotech AG, a company pioneering antibody-drug conjugate (ADC)-linker technology, announced today that it has recruited Dr. ...
Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, is pleased to announce the appointment of Filippo Mulinacci, Ph.D., MBA as chief business officer. ...
(Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in two upcoming investor conferences. ...
(Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces the Company has been awarded ‘Biotech Company of the Year 2022’ at the annual LSX, European Lifestars Awards Ceremony, held on the 14th of ...
For example, an antibody can be engineered to improve binding affinity to a particular antigen, to conjugate a drug, or to prolong the time antibodies reside in circulation. ...
Those fortunate presented astonishing innovations ranging from antibody-drug conjugates as next-generation cancer therapy (Tubulis) to quantum computing. ...
(Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that data from the Company’s compassionate use program on anti-leukemic activity of STRO-002, a novel folate receptor-α (FR-α) targeting ADC, in infants and children with ...